Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jean Bourbeau, Mohit Bhutani, Paul Hernandez, Shawn D. Aaron, Meyer Balter, Marie-France Beauchesne, Anthony D’Urzo, Roger Goldstein, Alan Kaplan, François Maltais, Don D. Sin & Darcy D. Marciniuk. (2019) Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 3:4, pages 210-232.
Read now
Read now
Maria Gabriella Matera, Luigino Calzetta, Ermanno Puxeddu, Paola Rogliani & Mario Cazzola. (2018) A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety 17:5, pages 509-517.
Read now
Read now
Brian W. Carlin, Sandra K. Schuldheisz, Imre Noth & Gerard J. Criner. (2017) Individualizing the selection of long-acting bronchodilator therapy for patients with COPD: considerations in primary care. Postgraduate Medicine 129:7, pages 725-733.
Read now
Read now
Jean Bourbeau, Mohit Bhutani, Paul Hernandez, Darcy D. Marciniuk, Shawn D. Aaron, Meyer Balter, Marie-France Beauchesne, Anthony D'Urzo, Roger Goldstein, Alan Kaplan, François Maltais, Denis E. O'Donnell & Don D. Sin. (2017) CTS position statement: Pharmacotherapy in patients with COPD—An update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 1:4, pages 222-241.
Read now
Read now
Articles from other publishers (7)
Nobuhiko Fukuda, Nobuyuki Horita, Ayami Kaneko, Atsushi Goto, Takeshi Kaneko, Erika Ota & Kayleigh M Kew. (2023) Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2023:6.
Crossref
Crossref
Ian M. Adcock, Surya P. Bhatt, Ronald Balkissoon & Robert A. Wise. (2022) The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice. The American Journal of Medicine 135:3, pages 302-312.
Crossref
Crossref
Tanja Fens, Simon van der Pol, Janwillem W.H. Kocks, Maarten J. Postma & Job F.M. van Boven. (2019) Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. Value in Health 22:10, pages 1092-1101.
Crossref
Crossref
Yuji Oba, Edna Keeney, Namratta Ghatehorde & Sofia Dias. (2018) Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
Mario Cazzola, Josuel Ora, Ermanno Puxeddu & Paola Rogliani. (2017) Indacaterol/Glycopyrronium Combination for COPD. Pulmonary Therapy 3:1, pages 45-57.
Crossref
Crossref
Yuji Oba, Mario Fadila, Edna Keeney & Sofia Dias. (2017) Fixed-dose combination inhalers compared to long-acting bronchodilators for COPD: a network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Nobuyuki Horita, Atsushi Goto, Yuji Shibata, Erika Ota, Kentaro Nakashima, Kenjiro Nagai & Takeshi Kaneko. (2017) Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2018:2.
Crossref
Crossref